The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

BACKGROUND: Imatinib represents the first in a class of drugs targeted against chronic myelogenous leukemia to enter the clinic, showing excellent efficacy and specificity for Abl, Kit, and PDGFR kinases. Recent screens carried out to find off-target proteins that bind to imatinib identified the oxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Winger, Jonathan A, Hantschel, Oliver, Superti-Furga, Giulio, Kuriyan, John
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655291/
https://www.ncbi.nlm.nih.gov/pubmed/19236722
http://dx.doi.org/10.1186/1472-6807-9-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655291/
https://www.ncbi.nlm.nih.gov/pubmed/19236722
http://dx.doi.org/10.1186/1472-6807-9-7

Ejemplares similares